Drug Comparison · Last verified: April 14, 2026

By The RX Index Editorial Team · Last verified: April 14, 2026 · Pricing verified via LillyDirect · Foundayo data from FDA-approved prescribing information and ATTAIN-1 (NEJM, Sept 2025) · Retatrutide data from Eli Lilly TRIUMPH-4 topline results (Dec 2025, not yet peer-reviewed)

Orforglipron vs Retatrutide: Real Differences & What to Do Now (2026)

Orforglipron vs retatrutide comes down to one thing most comparison pages won’t say upfront: you can get one of these drugs today, and you can’t get the other.

Foundayo (orforglipron) is an FDA-approved daily GLP-1 pill available right now through LillyDirect, telehealth providers, and retail pharmacies. Self-pay starts at $149/month. In Phase 3 trials, it produced 12.4% average body weight loss at the highest dose over 72 weeks — about 27 lbs for the average participant.

Retatrutide is a once-weekly injectable triple agonist that produced 28.7% weight loss in Phase 3 — the highest number ever reported for any obesity drug, roughly 71 lbs on average. But it is not FDA-approved, not available at any legitimate pharmacy, and Eli Lilly has not publicly announced an FDA filing date. Analyst projections place potential approval no sooner than 2027.

Both are made by Eli Lilly. In our editorial assessment, they’re designed to serve different patients — orforglipron for accessibility, retatrutide for maximum efficacy. The rest of this page exists so you never have to open another tab.

Orforglipron vs Retatrutide: The Head-to-Head Comparison

Data assembled from ATTAIN-1 (NEJM, Sept 2025), TRIUMPH-4 topline results (Eli Lilly, Dec 2025), FDA prescribing information for Foundayo, and LillyDirect pricing. Sources cited for every row. Last verified April 14, 2026.

Sources: FDA.gov approval announcement (4/1/26), Foundayo prescribing information (DailyMed), ATTAIN-1 (NEJM, Sept 2025), TRIUMPH-4 topline results (Eli Lilly press release, Dec 2025), LillyDirect pricing page (verified 4/14/26). These are separate trials with different patient populations — not a head-to-head comparison.

Separate Phase 3 trials. Not a head-to-head study.

How Do Orforglipron and Retatrutide Actually Work?

Orforglipron activates one metabolic receptor — GLP-1 — as a once-daily pill. Retatrutide activates three receptors simultaneously — GLP-1, GIP, and glucagon — as a once-weekly injection. That third receptor is the whole story.

What This Means in Plain Language

How Much Weight Will You Actually Lose? The Honest Numbers

This is the section where we need to slow down, because the headline comparison — 12.4% vs 28.7% — is real but misleading without context.

Foundayo (Orforglipron): ATTAIN-1 Trial

Published in the New England Journal of Medicine, September 2025. Enrolled 3,127 adults with obesity or overweight (without diabetes). Over 72 weeks at the highest dose (17.2mg marketed dose):

• On-treatment (efficacy estimand): 12.4% body weight lost — about 27.3 lbs for the average participant
• All participants including dropouts (treatment-regimen estimand): 11.2% — about 25.0 lbs
• 59% of patients on the highest dose lost at least 10% of their body weight
• 18% lost 20% or more
• Up to 91% of participants with prediabetes at baseline achieved near-normal blood sugar levels

For real-world context: if you weigh 250 lbs, the on-treatment average translates to roughly 31 lbs lost. That moves you from a BMI of 40 to about 35.

Retatrutide: TRIUMPH-4 Trial

Eli Lilly topline press release, December 11, 2025. Phase 3 results from 445 adults with obesity/overweight AND knee osteoarthritis. Over 68 weeks:

Mean baseline weight was 248.5 lbs (BMI 40.4). For a 250-lb person: the 12mg on-treatment average translates to roughly 72 lbs lost — a BMI drop from 40 to about 29.

Why You Can’t Simply Compare These Numbers

These numbers come from different trials with different populations. ATTAIN-1 enrolled adults with obesity but without diabetes. TRIUMPH-4 enrolled adults with obesity AND knee osteoarthritis — a population with higher baseline BMI (40.4) that tends to lose more absolute weight. There is no head-to-head trial comparing these two drugs directly.

That said, the gap is large enough that the directional conclusion is clear: retatrutide produces substantially more weight loss than orforglipron. The question is whether that additional weight loss is worth the trade-offs — availability, route of administration, side effects, and cost.

Can You Actually Get These Drugs Right Now?

Retatrutide Approval Timeline (Projections Only)

These are projections based on analyst reports (Citi, BMO, UBS, Jefferies) and Lilly investor materials — not confirmed regulatory timelines. Lilly’s official position: retatrutide is investigational and legally available only to participants in authorized clinical trials.

Side Effects Head-to-Head: The Dysesthesia Difference

Both drugs cause the gastrointestinal side effects common to all GLP-1 medications — nausea, diarrhea, constipation, vomiting. These are typically worst during dose escalation and improve over time. But retatrutide introduces one side effect that doesn’t appear with any approved GLP-1: dysesthesia.

Sources: Foundayo prescribing information (DailyMed, April 2026) — pooled data from ATTAIN-1 and ATTAIN-2; TRIUMPH-4 topline results (Eli Lilly, Dec 2025). Different trials, different populations.

The Dysesthesia Signal — Unique to Retatrutide

Dysesthesia is an abnormal touch sensation — tingling, tenderness, “pins and needles,” skin sensitivity, or discomfort when touched normally. In TRIUMPH-4:

• 20.9% of patients on the 12mg dose experienced dysesthesia
• 8.8% on the 9mg dose
• 0.7% on placebo

This side effect does not appear at meaningful rates with semaglutide, tirzepatide, or orforglipron. Researchers believe it’s related to glucagon receptor activation — the component unique to retatrutide’s triple mechanism.

Foundayo Safety: What the Label Says

Foundayo carries a boxed warning for thyroid C-cell tumors (standard for the GLP-1 class). From the FDA-approved prescribing information:

What Will You Actually Pay?

Foundayo Pricing — Verified via LillyDirect, April 2026

• With commercial insurance: As low as $25/month using the Foundayo Savings Card (eligible commercially insured patients; governmental beneficiaries excluded)
• Medicare Part D: Eligible individuals may be able to get Foundayo for approximately $50/month beginning as soon as July 1, 2026, per Eli Lilly

How Foundayo Compares to Other GLP-1 Options

Note on compounded options: Compounded medications are not FDA-approved versions of brand-name drugs. They are produced by compounding pharmacies under different regulatory oversight.

Should You Start Foundayo Now or Wait for Retatrutide?

This is the question this page exists to answer. We’ve given you the data. Here’s the decision framework.

Who Should NOT Take Foundayo

Foundayo is not for everyone. The FDA-approved prescribing information specifies:

If any of these apply to you, that doesn’t mean you’re out of options. Injectable GLP-1s like Zepbound or Wegovy may still be appropriate depending on your specific situation. Take our matching quiz or talk with your healthcare provider.

What If You Want More Weight Loss Than Foundayo Delivers?

Fair question. If Foundayo’s 12.4% isn’t enough for your goals and you don’t want to wait for retatrutide, here’s what’s FDA-approved and available today:

Can You Switch From Foundayo to Retatrutide Later?

There is no published data on switching from orforglipron to retatrutide. That specific transition has not been studied. What we do have:

• ATTAIN-MAINTAIN trial (Eli Lilly, December 2025): Patients switching from injectable Wegovy to oral Foundayo maintained their weight loss, regaining an average of only 0.9 kg (about 2 lbs). Patients switching from Zepbound to Foundayo regained about 5.0 kg.
• Mechanism compatibility: Retatrutide activates all three receptors that orforglipron (GLP-1) and Zepbound (GLP-1 + GIP) individually target. A step-up from Foundayo to retatrutide would mean adding two additional receptor pathways, not switching mechanisms entirely.

The bottom line: starting Foundayo now does not lock you out of retatrutide later. No published data suggests prior GLP-1 use would reduce the effectiveness of a future triple-agonist medication, and any weight you lose in the interim gives you a better starting point.

How All of This Fits Into the Broader GLP-1 Landscape

Here’s where each option sits as of April 2026:

Weight loss figures from separate Phase 3 trials — cross-trial comparisons are directional, not definitive.

What Should You Do While Waiting for Retatrutide?

If you’ve decided retatrutide is what you ultimately want, here’s a practical plan for right now:

What We Actually Verified

Frequently Asked Questions

Still Not Sure Which GLP-1 Program Is Right for You?

Answer a few questions about your goals, preferences, and budget, and we’ll recommend the specific path — and specific provider — that fits your situation. Whether that’s Foundayo, an injectable, a compounded option, or something else entirely. No spam, no pressure, just a personalized action plan.